We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Serum MicroRNAs Predict Likelihood of Pregnant Women Developing Pre-Eclampsia

By LabMedica International staff writers
Posted on 02 Jun 2020
MicroRNA biomarkers have been identified in the blood of asymptomatic pregnant women that can be used to predict the potential onset of pre-eclampsia.

Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure and often a significant amount of protein in the urine. More...
When it arises, the condition begins after 20 weeks of pregnancy. In severe disease there may be red blood cell breakdown, a low blood platelet count, impaired liver function, kidney dysfunction, swelling, shortness of breath due to fluid in the lungs, or visual disturbances. Pre-eclampsia increases the risk of poor outcomes for both the mother and the baby. If left untreated, it may result in seizures at which point it is known as eclampsia. Ten to 15% of maternal mortality is associated with pre-eclampsia and eclampsia.

MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. In addition to miRNAs playing an essential role in tumor development, dysregulation of certain miRNAs has been associated with many different diseases, such as dementia, and cardiovascular conditions.

Development of effective prevention and treatment strategies for pre-eclampsia has been limited by the lack of accurate methods for identification of at-risk pregnancies. To correct this situation, investigators at the University of California, San Diego (USA) and colleagues at Sera Prognostics, Inc.(Salt Lake City, UT, USA), a biomedical company specializing in diagnostic tests for predicting risk of premature birth, performed small RNA sequencing (RNA-seq) of maternal serum extracellular RNAs (exRNAs) to discover and verify miRNAs differentially expressed in patients who later developed pre-eclampsia.

For this study, the investigators monitored 141 subjects (49 cases, 92 controls) in a discovery cohort and 71 subjects (24 cases, 47 controls) in a separate verification cohort. The subjects were asymptomatic pregnant women between 17 and 28 weeks of pregnancy.

Results of RNA-seq analysis of the subjects’ sera revealed two single-miRNA biomarkers (univariate) and 29 two-miRNA (bivariate) biomarkers that were able to predict later onset of pre-eclampsia. The majority of verified biomarkers contained the microRNA miR-155-5p, which had been reported to mediate the pre-eclampsia-associated repression of the enzyme endothelial nitric oxide synthase (eNOS) by tumor necrosis factor alpha (TNF-alpha). In addition, deconvolution analysis revealed that several verified miRNA biomarkers came from the placenta and were likely carried by placenta-specific extracellular vesicles.

“The ability to identify pregnancies at high risk for developing pre-eclampsia would be of great value to patients and their doctors to better personalize prenatal care,” said senior author Dr. Louise Laurent, professor of obstetrics, gynecology, and reproductive sciences at the University of California, San Diego. “This would enable prompt detection and optimal management of pregnancies that develop pre-eclampsia. And the information could be used to better identify participants for research studies testing preventive therapies.”

“We look forward to the clinical validation of these novel miRNA biomarkers of pre-eclampsia through our continued collaboration with Dr. Laurent and the University of California, San Diego,” said Dr. Jay Boniface, chief scientific officer at Sera Prognostics. “Innovative bioinformatics approaches have enabled their discovery and the prospect of creating predictors for individualized risk of pregnancy complications.”

The pre-eclampsia study was published in the May 19, 2020 online edition of the journal Cell Reports Medicine.

Related Links:
University of California, San Diego
Sera Prognostics, Inc.



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.